Seeking Alpha
06 Oct 2026, 05:00 UTC · 9h ago
Impact · against what's priced in
The modest September IPO activity and Adarx's positive debut are insufficient to trigger a valuation rerating for the broader market. The data confirms a stagnant deal flow environment that is already well-understood by investors.
Scored by the NIS engine · methodology.
Search tags
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Adarx Pharmaceuticals shares gained 13.8% on their first day after pricing at $17.00 per share.
Priced inanalysis of September results
So whatPositive debut performance often boosts valuation multiples for comparable biotech peers in the short term.
More positive than 79% of claims this week
The six-month IPO pipeline grew to 71 companies seeking to raise approximately $2.2 billion in aggregate proceeds.
Continue reading
5 related stories
Priced inanalysis of September results
So whatWith only six deals closing in September, the current backlog represents nearly 12x the monthly deal volume.
More positive than 53% of claims this week
Six IPO offerings in September raised $1.9 billion in aggregate proceeds.
Priced inanalysis of September results
So whatThe average deal size increased by roughly $14 million per offering compared to August.
More positive than 44% of claims this week
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
